Saturday, August 18, 2018 10:40:31 PM
Celgene had a small Phase 2 trial for Otezla (apremilast, CC-10004) there were only 30 subjects in the treatment phase.
...the proportion of subjects achieving PASI 75 was 30%....
...9 subjects achieved PASI 75....
...several subjects (4) dropped out early (on or prior to week 4) due to intolerability (gastrointestinal effects) or withdrawn consent....
That is very similar to the proportion of subjects achieving
PASI 75 in the larger Otezla Phase 4 trials.
https://media.celgene.com/content/uploads/CC-10004-PSOR-004-Synopsis-Redacted.pdf
Now compare those results to the Prurisol Phase 2 trial results.
https://static1.squarespace.com/static/5715352e20c647639137f992/t/583ddc8303596e5fc7e8bf06/1480449160455/Cellceutix_Corporate_Slide+Deck_DERMATOLOGY_November+2016+Website+Vers.pdf
Good luck and GOD bless,
George
Recent IPIX News
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
